- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00644605
A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension
A Multinational, Multi-centre, Randomised, Double-blind, Double-dummy, Placebo-controlled Study to Assess the Efficacy and Safety of 20, 40, and 80mg TID Sildenafil in the Treatment of Pulmonary Arterial Hypertension in Subjects Aged 18 Years and Over
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Verwacht)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
New South Wales
-
Darlinghurst, New South Wales, Australië, 2010
- Pfizer Investigational Site
-
-
Victoria
-
Melbourne, Victoria, Australië, 3004
- Pfizer Investigational Site
-
-
-
-
-
Bruxelles, België, 1070
- Pfizer Investigational Site
-
Leuven, België, 3000
- Pfizer Investigational Site
-
-
-
-
SP
-
Sao Paulo, SP, Brazilië, 05403-900
- Pfizer Investigational Site
-
-
-
-
-
Kobenhavn, Denemarken, 2100
- Pfizer Investigational Site
-
-
-
-
-
Berlin, Duitsland, 13353
- Pfizer Investigational Site
-
Giessen, Duitsland, 35385
- Pfizer Investigational Site
-
Giessen, Duitsland, 35392
- Pfizer Investigational Site
-
Hannover, Duitsland, 30625
- Pfizer Investigational Site
-
Leipzig, Duitsland, 04103
- Pfizer Investigational Site
-
-
-
-
-
Clamart, Frankrijk, 92141
- Pfizer Investigational Site
-
-
-
-
Pest
-
Budapest, Pest, Hongarije, 1529
- Pfizer Investigational Site
-
-
Zala
-
Zalaegerszeg, Zala, Hongarije, 8900
- Pfizer Investigational Site
-
-
-
-
-
Shatin N T, Hongkong
- Pfizer Investigational Site
-
-
-
-
-
Petach Tikva, Israël, 49100
- Pfizer Investigational Site
-
Tel Hashomer, Israël, 52621
- Pfizer Investigational Site
-
-
-
-
-
Bologna, Italië, 40138
- Pfizer Investigational Site
-
Pisa, Italië, 56124
- Pfizer Investigational Site
-
Pisa, Italië, 56126
- Pfizer Investigational Site
-
-
-
-
-
Suwon, Korea, republiek van, 442-721
- Pfizer Investigational Site
-
-
-
-
-
Kuala Lumpur, Maleisië, 59100
- Pfizer Investigational Site
-
-
-
-
-
Tlalpan, Mexico
- Pfizer Investigational Site
-
-
-
-
-
Amsterdam, Nederland, 1081 HV
- Pfizer Investigational Site
-
-
-
-
-
Oslo, Noorwegen, NO-0027
- Pfizer Investigational Site
-
-
-
-
-
Katowice, Polen, 40-057
- Pfizer Investigational Site
-
Warszawa, Polen, 01-138
- Pfizer Investigational Site
-
Warszawa, Polen, 03-709
- Pfizer Investigational Site
-
Zabrze, Polen, 41-800
- Pfizer Investigational Site
-
-
-
-
-
Singapore, Singapore, 168752
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, Spanje, 08035
- Pfizer Investigational Site
-
Barcelona, Spanje, 08036
- Pfizer Investigational Site
-
Madrid, Spanje, 28041
- Pfizer Investigational Site
-
-
-
-
-
Prague 4, Tsjechië, 140 00
- Pfizer Investigational Site
-
Prague 4, Tsjechië, 140 21
- Pfizer Investigational Site
-
-
-
-
-
Glasgow, Verenigd Koninkrijk, G11 6NT
- Pfizer Investigational Site
-
HIGH Heaton, Newcastle-upon-tyne, Verenigd Koninkrijk, NE7 7DW
- Pfizer Investigational Site
-
-
Cambridgeshire
-
Papworth Everard, Cambridgeshire, Verenigd Koninkrijk, CB3 8RE
- Pfizer Investigational Site
-
-
South Yorkshire
-
Sheffield, South Yorkshire, Verenigd Koninkrijk, S10 2JF
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35233
- Pfizer Investigational Site
-
Birmingham, Alabama, Verenigde Staten, 35294
- Pfizer Investigational Site
-
Birmingham, Alabama, Verenigde Staten, 35294-0006
- Pfizer Investigational Site
-
-
California
-
La Jolla, California, Verenigde Staten, 92037
- Pfizer Investigational Site
-
La Jolla, California, Verenigde Staten, 92093
- Pfizer Investigational Site
-
Los Angeles, California, Verenigde Staten, 90095
- Pfizer Investigational Site
-
Los Angeles, California, Verenigde Staten, 90033
- Pfizer Investigational Site
-
Los Angeles, California, Verenigde Staten, 90024
- Pfizer Investigational Site
-
San Diego, California, Verenigde Staten, 92037
- Pfizer Investigational Site
-
Torrance, California, Verenigde Staten, 90502
- Pfizer Investigational Site
-
Torrance, California, Verenigde Staten, 90509
- Pfizer Investigational Site
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80010
- Pfizer Investigational Site
-
Denver, Colorado, Verenigde Staten, 80262
- Pfizer Investigational Site
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60612
- Pfizer Investigational Site
-
-
Louisiana
-
Shreveport, Louisiana, Verenigde Staten, 71103
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21205
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02111
- Pfizer Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- Pfizer Investigational Site
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Pfizer Investigational Site
-
-
New York
-
New York, New York, Verenigde Staten, 10032
- Pfizer Investigational Site
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27710
- Pfizer Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37232
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Pfizer Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53215
- Pfizer Investigational Site
-
-
-
-
-
Cape Town, Zuid-Afrika, 7700
- Pfizer Investigational Site
-
Johannesburg, Zuid-Afrika, 2193
- Pfizer Investigational Site
-
Parow, Zuid-Afrika
- Pfizer Investigational Site
-
-
-
-
-
Goteborg, Zweden, 413 45
- Pfizer Investigational Site
-
Molndal, Zweden, 431 80
- Pfizer Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Included patients had primary pulmonary arterial hypertension, pulmonary hypertension secondary to connective tissue disease, or pulmonary hypertension with surgical repair at least 5 years previously; a mean pulmonary artery pressure greater than or equal to 25 mmHg and a pulmonary artery wedge pressure of less than or equal to 15 mmHg at rest, via right heart catheterisation within 21 days prior to randomisation; and a baseline 6-Minute Walk test distance of 100 m to 450 m.
Exclusion Criteria:
Subjects with congenital heart disease, pulmonary hypertension due to thromboembolism, HIV, chronic obstructive airway disease, congestive heart failure or schistosomiasis; subjects with significant (ie > 2+) valvular disease other than tricuspid regurgitation or pulmonary regurgitation; and acutely decompensated heart failure within the previous 30 days; subjects with pulmonary hypertension secondary to any other etiology other than those specified in the inclusion criteria.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: Arm 2
|
sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
|
Actieve vergelijker: Arm 1
|
sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
|
Placebo-vergelijker: Arm 4
|
placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
|
Actieve vergelijker: Arm 3
|
sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Change from baseline in exercise capacity, as measured by distance walked in six minutes (6-Minute Walk test).
Tijdsspanne: Week 12
|
Week 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Change from baseline in mean pulmonary arterial pressure
Tijdsspanne: Week 12
|
Week 12
|
Time from randomisation to the first occurrence of clinical worsening (death or lung transplantation or hospitalisation due to pulmonary hypertension or initiation of prostacyclin therapy or initiation of bosentan therapy)
Tijdsspanne: Week 0 to 12
|
Week 0 to 12
|
Change from baseline in the BORG dyspnoea score
Tijdsspanne: Week 12
|
Week 12
|
Change from baseline in pulmonary hypertension criteria for functional capacity and therapeutic class
Tijdsspanne: Week 12
|
Week 12
|
Change from baseline in the 8 dimensions of SF-36 (Physical functioning, Role functioning, Bodily pain, General health, Vitality, Social functioning, Mental health and Reported health transition)
Tijdsspanne: Week 4 and Week 12
|
Week 4 and Week 12
|
Change from baseline at Weeks 4 and 12 in the 5 dimensions of ED5Q (Mobility, Self care, Usual Activities, Pain/Discomfort and Anxiety/Depression)
Tijdsspanne: Week 4 and Week 12
|
Week 4 and Week 12
|
Patient overall preference assessment
Tijdsspanne: Week 12
|
Week 12
|
Change in Chronic Use of Background Therapy for Pulmonary Arterial Hypertension
Tijdsspanne: throughout the study
|
throughout the study
|
Change from baseline in hemodynamic parameters
Tijdsspanne: Week 12
|
Week 12
|
Medewerkers en onderzoekers
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Hart-en vaatziekten
- Vaatziekten
- Ziekten van de luchtwegen
- Longziekten
- Hypertensie
- Pulmonale arteriële hypertensie
- Hypertensie, pulmonaal
- Moleculaire mechanismen van farmacologische werking
- Vaatverwijdende middelen
- Urologische middelen
- Enzymremmers
- Fosfodiësteraseremmers
- Fosfodiësterase 5-remmers
- Sildenafil Citraat
Andere studie-ID-nummers
- A1481140
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op sildenafil
-
University of PennsylvaniaWalter Reed National Military Medical CenterWerving
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); PfizerVoltooid
-
Rambam Health Care CampusOnbekend
-
Pfizer's Upjohn has merged with Mylan to form Viatris...VoltooidErectiestoornissenSingapore
-
Northwestern UniversityVoltooidHand Voet Huid ReactieVerenigde Staten
-
The Cleveland ClinicVoltooidPulmonale hypertensie | Diffuse parenchymale longziekteVerenigde Staten
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Voltooid
-
iX Biopharma Ltd.Linear Clinical ResearchVoltooidErectiestoornissenAustralië
-
Rigshospitalet, DenmarkGlostrup University Hospital, CopenhagenVoltooidBecker spierdystrofieDenemarken
-
N4 Pharma UK Ltd.BDD Pharma LtdVoltooidErectiestoornissenVerenigd Koninkrijk